CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

The 10-year yield declined 0.095 percentage point to 4.364% today. The price rose 24/32 to 99 3/32. --Largest one-day yield decline since Monday, April 14, 2025 ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

--Traded as high as $465.69; highest intraday level since July 10, 2024, when it hit $466.46 ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Elon Musk has continued to lead as the world's highest-paid CEO, with $23,5 billion in a recent ranking, which showed the top ...

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than ...